ArticleImmunotherapy2025

First-line pembrolizumab for metastatic NSCLC in lower-middle-income countries: bridging the efficacy-effectiveness gap.

Ullas Batra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.